Alkermes, Inc.
Clinical trials sponsored by Alkermes, Inc., explained in plain language.
A biopharmaceutical company developing treatments for central nervous system diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New combo pill aims to curb weight gain in teens on antipsychotics
Disease control Recruiting nowThis study tests whether a combination drug called OLZ/SAM (olanzapine plus samidorphan) causes less weight gain than olanzapine alone in teenagers with schizophrenia or bipolar I disorder. About 220 teens aged 10-17 will take either the combo or olanzapine for 52 weeks. The main…
Phase: PHASE3 • Sponsor: Alkermes, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Could a new pill tame adult ADHD symptoms?
Disease control Recruiting nowThis phase 2 trial is testing whether an experimental tablet called ALKS 7290 can reduce ADHD symptoms in adults. About 312 adults with ADHD will take either the drug or a placebo daily for 4 weeks. Researchers will measure changes in symptom scores and watch for side effects to …
Phase: PHASE2 • Sponsor: Alkermes, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a Two-Drug combo help teens with severe mental illness?
Disease control AVAILABLEThis expanded access program offers continued treatment with OLZ/SAM, a combination of olanzapine and samidorphan, to adolescents with schizophrenia or bipolar I disorder who have already completed a year-long study of the drug. The goal is to provide ongoing access to the medica…
Sponsor: Alkermes, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New narcolepsy pill aims to banish daytime drowsiness
Symptom relief Recruiting nowThis study tests a new tablet called ALKS 2680 to see if it can reduce daytime sleepiness in adults with narcolepsy type 2. About 176 participants will receive either the study drug or a placebo for 12 weeks. The main goal is to measure how well they can stay awake using a standa…
Phase: PHASE3 • Sponsor: Alkermes, Inc. • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
New pill shows promise for keeping people with narcolepsy awake longer
Symptom relief Recruiting nowThis study is testing the long-term safety and how well ALKS 2680 works over time in people with narcolepsy type 1, type 2, or idiopathic hypersomnia. Participants take a once-daily tablet at different doses. The goal is to see if the drug remains safe and effective for staying a…
Phase: PHASE2, PHASE3 • Sponsor: Alkermes, Inc. • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
New pill aims to fight daytime sleepiness and sudden muscle collapse
Symptom relief Recruiting nowThis phase 3 trial tests whether a daily tablet called ALKS 2680 can reduce daytime sleepiness and cataplexy (sudden muscle weakness) in 150 adults with narcolepsy type 1. Participants will take the drug or a placebo for 12 weeks, and researchers will measure changes in sleep tes…
Phase: PHASE3 • Sponsor: Alkermes, Inc. • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
New pill aims to keep narcolepsy patients awake and steady
Symptom relief Recruiting nowThis phase 3 trial tests whether a daily tablet called ALKS 2680 can reduce severe daytime sleepiness and sudden muscle weakness (cataplexy) in adults with narcolepsy type 1. About 150 participants will receive either the drug or a placebo for 12 weeks. The study measures improve…
Phase: PHASE3 • Sponsor: Alkermes, Inc. • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
New pill aims to fight excessive daytime sleepiness
Symptom relief Recruiting nowThis study tests a new drug called ALKS 2680 to see if it can safely reduce daytime sleepiness in people with idiopathic hypersomnia, a condition causing excessive sleepiness without clear cause. About 126 participants will receive either the drug or a placebo daily for 8 weeks. …
Phase: PHASE2 • Sponsor: Alkermes, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC